More -- Of The Changing Of The Generational Guard -- At Merck's Science / Discovery Offices... Roy Baynes Edition, This Morning...

We have long followed Dr. Perlmutter's career arc -- from Merck to Amgen, and back again (and now recently retired, from there) -- for over more than a decade. We learned this morning (via EndPoints) that the generational turnover -- at Merck continues. [These gents at right two worked on the launch of Keytruda, among many other wildly successful therapies, while at Kenilworth.]

One of Dr. Perlmutter's long time chief collaborators, Roy Baynes, is leaving Merck -- and joining him at Eikon as an EVP and Chief Medical Officer. . .where together, they will work on super-resolution microscopy based on advanced optics and machine learning techniques -- to track the real-time movements of proteins, in live cells. [This is en vivo imaging, as I understand it.]

The hope at this biotech startup is to discover new therapies, primarily biologics, via such investigational imaging.

As ever, time will tell -- but the two of them boast (combined) over 40 years of success after success at Mother Merck. So do stay tuned. . . onward, grinning -- ever. . . grinning.

नमस्ते